Product Description
Ticagrelor (Brilique™, Brilinta®), a cyclopentyl-triazolopyrimidine, is an orally active, reversible, and selective adenosine diphosphate (ADP) receptor antagonist indicated for use in patients with acute coronary syndromes (ACS). Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25672642/)
Mechanisms of Action: P2Y12 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Acute Coronary Syndrome | Coronary Artery Disease | Coronary Disease | Coronary Thrombosis | Myocardial Infarction | Thrombosis | Ischemic Stroke | Ischemic Attack, Transient | Stroke | General Diabetes | Type 2 Diabetes
Known Adverse Events: Dyspnea | Injuries/wounds Unspecified
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Myocardial Infarction|Pneumonia|Thrombosis
Phase 2: Atherosclerosis|Carotid Artery Thrombosis|Carotid Stenosis|Coronary Stenosis|Coronary Thrombosis|Myocardial Ischemia
Phase 1: Acute Coronary Syndrome|Healthy Volunteers|Oncology Solid Tumor Unspecified|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507015-35-00 | P3 |
Not yet recruiting |
Coronary Artery Disease |
2029-07-30 |
|
| ANGIODAPT | P3 |
Active, not recruiting |
Coronary Artery Disease |
2029-07-21 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|Influenza, Human|COVID-19 |
2026-02-01 |
|
| TADCLOT | P3 |
Recruiting |
Thrombosis|Myocardial Infarction |
2024-11-15 |